Treating hepatitis C in the prison population is cost-saving

Hepatology

Volumn 48, Issue 5, 2008, Pages 1387-1395

  Tan, Jennifer A ^a   Joseph, Tom A ^a   Saab, Sammy ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; GENOTYPE; HEALTH CARE ACCESS; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; POPULATION RESEARCH; PRIORITY JOURNAL; PRISON; PROBABILITY; QUALITY OF LIFE; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; PREVALENCE; PRISONER; REVIEW; STATISTICS;

ADULT; AGED; ANTIVIRAL AGENTS; COST CONTROL; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MARKOV CHAINS; MIDDLE AGED; PREVALENCE; PRISONERS; UNITED STATES;

EID: 56149111923     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22509     Document Type: Article

References (60)

1. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006;144:762-769.
2. Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002;92:1789-1794.
3. U.S. Department of Justice. Prison and jail inmates at midyear 2006. Bureau of Justice Statistics Bulletin, June 2007. Available at: http://www.ojp.usdoj.gov/bjs/abstract/pjim06.htm. Accessed July 2008.
4. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-1569.
5. Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Morb Mortal Wkly Rep 2003;52(RR-1):1-36.
6. Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: A review of epidemiology and prevention. AIDS 2005;19(Suppl 3):S41-S46.
7. Fox RK, Currie SL, Evans J, Wright TL, Tobler L, Phelps B, et al. Hepatitis C virus infection among prisoners in the California State Correctional System. Clin Infect Dis 2005;41:177-186.
8. Hammett TM. Adopting more systematic approaches to hepatitis C treatment in correctional facilities. Ann Intern Med 2003;138:235-236.
9. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med 1999;28:92-100.
10. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-237.
11. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-432.
12. Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, et al. A health economic model to assess the cost-effectiveness of PEG IFN α-2a and ribavirin in patients with mild chronic hepatitis C. J Viral Hepat 2007;14:523-536.
13. Lidgren M, Hollander A, Weiland O, Jönsson B. Productivity improvements in hepatitis C treatment: Impact on efficacy, cost, cost-effectiveness and quality of life. Scand J Gastroenterol 2007;42:867-877.
14. Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis 2006;38:497-505.
15. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003;17:687-694.
16. Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004;22:257-265.
17. Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg 2004;67:1-8.
18. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon α-2a and ribavirin compared with interferon α-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004;99:1490-1496.
19. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 2004;8:iIi-iv, 1-125.
20. Hornberger J, Farci P, Prati D, Zeuzem S, Green J, Patel KK. The economics of treating chronic hepatitis C patients with peginterferon α-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepat 2006;13:377-386.
21. Lin WA, Tarn YH, Tang SL. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24:1483-1493.
22. Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: A cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy 2007;27:813-824.
23. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost-effectiveness of interferon-alpha or peg-interferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-1338.
24. U.S. Department of Justice. Prison and jail inmates at midyear 2005. Bureau of Justice Statistics Bulletin, May 2006. Available at: http://www.ojp.usdoj.gov/bjs/abstract/pjim05.htm. Accessed July 2008.
25. Sterling RK, Brown RS, Hofmann CM, Luketic VA, Stravits RT, Sanyal AJ, et al. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: Development of a strategy for the evaluation and treatment of inmates with HCV. Am J Gastroenterol 2005;100:313-321.
26. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med 2003;138:187-190.
27. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991;13:372-374.
28. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. HEPATOLOGY 1994;19:1513-1520.
29. Kim AI, Saab S. Treatment of hepatitis C. Am J Med 2005;118:808-815.
30. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
31. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al, and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358;958-965.
32. Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347;975-982.
33. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140:346-355.
34. Centers for Disease Control. United States life tables, 2003. National Vital Statistics Reports, April 2006. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/life/1966.htm. Accessed July 2008.
35. Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison - a high risk of death for former inmates. N Engl J Med 2007;356:157-165.
36. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzela G, et al. Sustained virological response to inteferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. HEPATOLOGY 2007;45:579-587.
37. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684.
38. National HCV Prison Coalition. State-by-state HCV treatment guidelines. Available at: Http://www.hcvinprison.org. Accessed July 2008.
39. Federal Bureau of Prisons. Guidelines for the prevention and treatment of viral hepatitis. Federal Bureau of Prisons - Clinical Practice Guidelines, October 2005. Available at: Http://www.bop.gov/news/PDFs/ hepatitis.pdf. Accessed July 2008.
40. Baillargeon J, Soloway RD, Paar D, Giordano TP, Murray O, Grady J, et al. End-stage liver disease in a state prison population. Ann Epidemiol 2007;17:808-813.
41. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-865.
42. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004;94:1218-1223.
43. Vlahov D, Nelson KE, Quinn TC, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol 1993;9:566-569.
44. Armstrong GL, Alter MJ, McQuillan GM, Margold HS. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000;31:777-782.
45. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. Ann Intern Med 2000;133:655-675.
46. Wright M, Grieve R, Roberts J, Main J, Thomas HC, on behalf of the UK Mild Hepatitis C Trial Investigators. Health benefits of antivital therapy for mild chronic hepatitis C: Randomized controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii.
47. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. HEPATOLOGY 1999;30:1318-1324.
48. Drug Topics Red Book. Montvale, NJ: Medical Economics; 2007.
49. U.S. Department of Labor Bureau of Labor Statistics. Consumer price index calculator. Available at: Http://www.bls.gov. Accessed July 2008.
50. Hoover D, Crystal S, Kumar R. Medical expenditures during the last year of medical expenditures during the last year of life: Findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002;37: 1625-1642.
51. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: Risks, bene.ts and costs. JAMA 1998;280:2088-2093.
52. Conjeevaram HS, Fried MW, Jeffers IJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-477.
53. Sterling RK, Hoffman CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: Can compliance overcome racial differences to response? Am J Gastroenterol 2004;99:866-872.
54. Kraus MR, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I, Scheurlen M. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: A randomized, double-blind, placebo-controlled study. Gut 2008;57:531-536.
55. Internet Drug News.com. Antidepressants drug database. Available at: http://www.coreynahman.com/antidepressantdrugsdatabase.html. Accessed July 2008.
56. U.S. Department of Justice. Mental health problems of prison and jail inmates. Bureau of Justice Statistics Special Report, September 2006. Available at: Http://www.ojp.gov/bjs/pub/pdf/mhppji.pdf. Accessed July 2008.
57. Thein HH, Butler TO, Krahn M, Rawlinson W, Levy MH, Kaldor JM, et al. The effect of hepatitis C virus infection on health-related quality of life in prisoners. J Urban Health 2006;83:275-288.
58. U.S. Department of Justice. Hepatitis testing and treatment in state prisons. Bureau of Justice Statistics Special Report, April 2004. Available at: Http://www.ojp.usdoj.gov/bjs/pub/pdf/httsp.pdf. Accessed July 2008.
59. Gustafson, Alan. Lawsuit spurs top-rank care to fight disease. Statesman Journal [scerial online], Nov. 12, 2007. Available at: http://www.statesmanjournal.com/apps/pbcs.dll/article?AID=/20071112/ NEWS/711120329/100. Accessed December 17, 2007.
60. The body. The complete HIV/AIDS resource. Available at: Http://www.thebody.com/content/art31262.html#hcv_inmates. Accessed July 2008.